Clinical study on Chronic Obstuctive Lung Disease (COLD)
15-03-2011
Kronisk obstruktiv lungsjukdom (KOL)
Valkion Air devices are being used in an ongoing clinical study to test effects on lung capacity and inflammatory markers in the blood on patients suffering from COLD. Early results indicate significant improvements.
COLD is caused by noxious particles or gas, most commonly from tobacco smoke but also occupational exposures and air pollution, which triggers an abnormal inflammatory response in the lung. The most common symptom of COLD is shortness of breath.
Valkion ab is the world leader in Singlet Oxygen Energy solutions and applications. Our mission is to harness the power of nature, enabling people everywhere to enjoy a better quality of life. Since 1988, we have been dedicated to developing and offering solutions which replicate the natural process of photosensitization. From our base in Sweden, we produce and supply products across the world. True to the vision of our founder, Tony van der Valk, Valkion ab re-invests a significant share of its net income into research and development.
March 7, 2011 Växjö, Sweden